Best available Treatment (BAT)

DRUG3 trials

Sponsors

Mats Remberger, Incyte Corporation, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions

Acute Graft-Versus-Host DiseaseAllogeneic Hematopoietic Stem Cell TransplantationChronic Graft-versus-host-diseaseGVHD, AcuteGraft-Versus-Host DiseaseSteroid-Refractory Acute Graft-Versus-Host Disease

Phase 2

Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT

TerminatedNCT04118556

Mats RembergerGVHD, Acute

Start: 2021-12-01End: 2026-04-29Updated: 2026-05-06

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

RecruitingNCT07124078

Incyte CorporationChronic Graft-versus-host-disease

Start: 2026-05-31End: 2029-07-31Target: 60Updated: 2026-05-07

Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

RecruitingNCT07572669

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcute Graft-Versus-Host Disease, Allogeneic Hematopoietic Stem Cell Transplantation, Graft-Versus-Host Disease +1

Start: 2025-09-01End: 2027-09-01Target: 42Updated: 2026-05-07